SCHEMBL23934134

SCHEMBL23934134

CCCC(C)(C)Oc1cccc(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
ACHE P22303 1/20 0.42
MAOB P27338 5/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 2/20 0.40
CMA1 P23946 1/20 0.40
DRD2 P14416 1/20 0.40
IDO1 P14902 1/20 0.40
AGXT P21549 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
MTNR1B P49286 1/20 0.39
APP P05067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11659680 0.93 PPARA (0.39) CNR1CNR2MAOBCYP3A4TSHR
SCHEMBL19387702 0.81 KMT2A (0.45) CNR1CNR2LMNAMAPK1DRD2
SCHEMBL11620191 0.81 MAOB (0.37) CNR1CNR2ACHEMAOB
SCHEMBL15356133 0.79 NPC1 (0.40) CNR1CNR2LMNAMAPK1SMN1; SMN2
SCHEMBL1452863 0.79 LTA4H (0.39) TAAR1TSHR
SCHEMBL5644608 0.79 CNR1 (0.52) CNR1CNR2ACHEMAOBCA1
SCHEMBL23934136 0.78 ALDH1A1 (0.36) ALDH1A1LMNADRD2SMN1; SMN2MTNR1B
SCHEMBL19185668 0.78 L3MBTL1 (0.48) MAOBALDH1A1LMNAIDO1
SCHEMBL678558 0.77 ACHE (0.52) ACHEMAOBCA1CA2CA7
SCHEMBL863137 0.77 PPARG (0.37) ACHEMAOBALDH1A1CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312511-A1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2023-10-05 US disclosed
US-20210323941-A1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE THE UNIVERSITY OF KANSAS 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323941-A1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE SLC6A3, DRD3, CHRM2 CNR1 133/4885CNR2 238/4885ACHE 434/4885
US-20230312511-A1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE SLC6A3, DRD3, DRD2 CNR1 121/4885CNR2 237/4885ACHE 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.